Sequoia Financial Advisors LLC Has $938,000 Stock Holdings in GSK plc (NYSE:GSK)

Sequoia Financial Advisors LLC boosted its holdings in shares of GSK plc (NYSE:GSK) by 2.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 22,937 shares of the pharmaceutical company’s stock after acquiring an additional 577 shares during the period. Sequoia Financial Advisors LLC’s holdings in GSK were worth $938,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. 1832 Asset Management L.P. grew its holdings in GSK by 9.1% during the 1st quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock worth $132,000 after acquiring an additional 257 shares during the period. Boltwood Capital Management grew its holdings in GSK by 2.5% during the 2nd quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock worth $429,000 after acquiring an additional 270 shares during the period. J.W. Cole Advisors Inc. grew its holdings in GSK by 4.7% during the 1st quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company’s stock worth $261,000 after acquiring an additional 271 shares during the period. First Affirmative Financial Network boosted its position in shares of GSK by 4.7% during the second quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock worth $245,000 after purchasing an additional 283 shares in the last quarter. Finally, Chapin Davis Inc. boosted its position in shares of GSK by 2.2% during the first quarter. Chapin Davis Inc. now owns 14,231 shares of the pharmaceutical company’s stock worth $610,000 after purchasing an additional 300 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Performance

Shares of GSK stock opened at $37.51 on Friday. The company has a market cap of $77.74 billion, a PE ratio of 13.59, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.99. The company has a 50 day moving average of $41.20 and a 200-day moving average of $41.16. GSK plc has a 1-year low of $33.67 and a 1-year high of $45.92.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The firm had revenue of $9.95 billion during the quarter, compared to analysts’ expectations of $9.49 billion. As a group, equities research analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 10th. Shareholders of record on Friday, August 16th were issued a $0.3843 dividend. This represents a $1.54 dividend on an annualized basis and a yield of 4.10%. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, August 16th. GSK’s dividend payout ratio (DPR) is presently 55.80%.

Insiders Place Their Bets

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the company’s stock in a transaction on Friday, September 27th. The shares were purchased at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on GSK shares. Argus raised shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Jefferies Financial Group lifted their price target on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Barclays raised shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Finally, UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.